Creative Commons source reading · Neurodegeneration biomarkers and longitudinal studies
Plasma β-amyloid, tau, neurodegeneration biomarkers and inflammatory factors of probable Alzheimer's disease dementia in Chinese individuals.
Qingling Sun; Jingnian Ni; Mingqing Wei; Siwei Long; Ting Li; Dongsheng Fan; Tao Lu; Jing Shi; Jinzhou Tian
Originally published in Frontiers in aging neuroscience · 2022-08-18
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Background Plasma-derived β-amyloid, tau, and neurodegeneration (ATN) biomarkers can accurately diagnose Alzheimer's disease (AD) and predict its progression. Few studies have investigated the relationship between plasma biomarkers and changes in plasma inflammatory markers in clinically diagnosed AD. Methods Seventy-four participants were recruited, including 30 mild-to-moderate AD dementia patients and 44 normal controls (NC). All participants underwent neuropsychological testing and blood sampling for biomarker testing. AD was clinically diagnosed according to the National Institute on Aging-Alzheimer's Association (NIA-AA) core criteria and required age-mismatched hippocampal atrophy. We performed Single Molecule Array (Simoa), an ultra-sensitive enzyme-linked immunosorbent assay (ELISA), to examine plasma ATN markers, including β-amyloid (Aβ) 40, Aβ42, p-tau181, total (t)-tau, neurofilament protein light chain (NfL), and inflammatory factors (TNF-α, IL-1β, IL-6, and IL-8).
Discussion
In this study, we compared the plasma levels of Aβ42, Aβ40, p-tau181, t-tau, and NfL in patients with probable AD dementia in mild-to-moderate stages with those in the NC group. The plasma ratio of Aβ42/Aβ40 was significantly decreased in the clinically diagnosed AD group, and the plasma levels of p-tau181 and NfL were significantly increased. T-tau, a biomarker of neurodegeneration, is usually elevated in the CSF, but it not significantly altered in the plasma samples in our study.
Conclusion
The level of plasma ATN biomarkers (Aβ42/40 ratio, p-tua181, and NfL) were significantly changed in clinically diagnosed AD patients and they all correlated with different domains of cognitive impairment. Plasma ATN biomarkers better differentiate mild-to-moderate AD dementia from NC when they are incorporated into diagnostic models together rather than applied individually. However, the expression of plasma inflammatory factors in AD patients requires further research.
Editorial reading guide
- Was the evidence cross-sectional, longitudinal or experimental?
- How did the authors account for age, disease stage and differences among participants?
